Coronary artery disease (CAD) is the leading cause of death and remains a major health problem worldwide. Myocardial perfusion imaging (MPI) with single photon emission tomography (SPECT) and positron emission tomography (PET) has been established as the main functional nuclear cardiology noninvasive technique for CAD over the past years. The studies has been shown that the use of MPI as a useful and important imaging modality for the diagnosis, risk stratification and treatment planning for CAD. The purpose of this article is to review properties of the radiopharmaceuticals used for myocardial perfusion imaging with SPECT and PET
